Business
Medicenna Reports MDNA11's Compelling Anti-Cancer Activity is Associated with Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update
MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that l...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update\n\n\n\n\n MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and effective anti-tumor activity\n \n\n\n\n MDNA11 has shown durable single agent activity, with a 30% (3 of 10) objective response rate (ORR) in the monotherapy dose expansion cohort in checkpoint-resistant patients (as of Dec. 5, 2024)\n \n\n\n\n Disease control rate (DCR) of 78% (7 of 9) in combination with Merck’s (known as MSD outside of Canada and the US) anti-PD-1 therapy, KEYTRUDA\n \n ®\n \n (pembrolizumab), includes one complete response, one partial response and five stable disease (as of Dec. 5, 2024)\n \n\n\n\n Safety Review Committee cleared the 120 µg/kg MDNA11 every two weeks in combination with KEYTRUDA\n \n ®\n \n as no dose-limiting toxicities (DLTs) have been observed to date\n \n\n\n\n To improve patient convenience, dosing of 120 µg/kg MDNA11 every three weeks as a monotherapy or in combination with KEYTRUDA\n \n ®\n \n is currently in progress\n \n\n\n\n Additional tumor types to be evaluated as part of ABILITY-1 Study in monotherapy and combination dose expansion cohorts with combination dose expansion expected to initiate mid 2025\n \n\n\n\n Updated safety and efficacy results of MDNA11 as a monotherapy and in combination with KEYTRUDA\n \n ®\n \n are to be presented at medical conferences in H1 2025\n \n\n\n TORONTO and HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA\n \n ®\n \n (pembrolizumab), in patients with advanced solid tumors. The data was presented in a late-breaking abstract at the inaugural American Association for Cancer Research Immuno-Oncology Conference (AACR...